Illumina completes acquisition of Genologics
Gene sequencing leader, Illumina, has announced that it has completed its acquisition of GenoLogics Life Science Software, providers of laboratory information systems (LIMS). The software suite will be integrated into Illumina's next-generation gene sequencing portfolio, and offers end-to-end data and information management control that interface directly with the Illumina workflow.&nbsp;
SAN DIEGO--(BUSINESS WIRE)--Illumina, Inc. (NASDAQ: ILMN) today announced it has completed the acquisition of GenoLogics Life Science Software Inc., a developer of industry leading laboratory information management systems (LIMS) for life sciences organizations.

"We look forward to working with the talented team at GenoLogics and to further integrate their life science software as part of the overall Illumina informatics solution," said Francis deSouza, President of Illumina. “Adopted by more than 120 genomic labs worldwide, GenoLogics’s Clarity LIMS software strengthens our industry leading portfolio of genetic analysis solutions.”

The completion of the acquisition demonstrates Illumina’s commitment to drive the adoption of sequencing in new markets and improve the genomic workflow. GenoLogics’ Clarity LIMS™ software enables lab efficiencies and improved sample throughput with increased accuracy, fast turnaround, sample traceability, and preconfigured instrument integrations.